A new study found semaglutide, sold as the popular diabetes and weight loss drugs Ozempic and Wegovy, was not linked to an increased risk of suicidal ideation compared with other weight loss drugs.

Use of the medicine semaglutide for weight loss or type 2 diabetes wasn’t associated with a higher risk of suicidal ideation than other medicines for those conditions in a large new review of US ...

Folks who take Ozempic or Wegovy for diabetes and weight loss need not worry about a higher risk of suicidal thoughts or feelings while on the medications, a new, large review finds. In the study ...

The obesity drug Wegovy can reduce the risk of severe heart problems by 20%, a pivotal study finds, paving the way for applications far beyond weight loss. AP/ Novo Nordisk. 3.

Drugs like Ozempic and Wegovy, called GLP-1 agonists, carry more benefits than risks when taken for their approved uses, ...

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients.

The results of a new clinical trial show that Wegovy is linked to a reduced risk of heart attack, stroke, and heart-related death. Ozempic, a drug similar to Wegovy, had a similar clinical ...

In 2024, Wegovy was also approved to help lower the risk of death due to heart disease, heart attack, and stroke in adults with known heart conditions who also have excess weight or obesity.

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20%, according to a large, international study paid for by Novo Nordisk, the drugmaker behind the product.

A pivotal new study suggests that the weight loss drug Wegovy cut the risk of heart attack, stroke or death from cardiovascular issues by 20 percent among overweight or obese people with heart ...

Medicare plans can now cover Wegovy for patients at risk of heart disease. Updated March 22, 2024 12:18 PM ET Originally published March 22, 2024 11:37 AM ET. By . Yuki Noguchi , ...